Danvatirsen is currently being investigated in an ongoing Phase II clinical trial (NCT02983578) in combination with the PDL1 inhibitor durvalumab, in patients with non-small cell lung cancer (NSCLC), advanced pancreatic cancer, and mismatch repair-deficient (dMMR) colorectal cancer (Table 3). This evidence concerns the gene CD274 and colorectal cancer.